Einar Haukås

1.2k total citations
17 papers, 129 citations indexed

About

Einar Haukås is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Einar Haukås has authored 17 papers receiving a total of 129 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Hematology, 6 papers in Oncology and 5 papers in Molecular Biology. Recurrent topics in Einar Haukås's work include Multiple Myeloma Research and Treatments (12 papers), Cancer Treatment and Pharmacology (3 papers) and Bone health and treatments (2 papers). Einar Haukås is often cited by papers focused on Multiple Myeloma Research and Treatments (12 papers), Cancer Treatment and Pharmacology (3 papers) and Bone health and treatments (2 papers). Einar Haukås collaborates with scholars based in Norway, Denmark and Finland. Einar Haukås's co-authors include Sigbjørn Berentsen, Ulla Randen, Henrik Birgens, Tor Henrik Anderson Tvedt, Geir E. Tjønnfjord, Eivind Galteland, Jon Hjalmar Sørbø, Inger Anne Næss, Robert Brudevold and Jakob Dalgaard and has published in prestigious journals such as Blood, Scientific Reports and British Journal of Cancer.

In The Last Decade

Einar Haukås

16 papers receiving 129 citations

Peers

Countries citing papers authored by Einar Haukås

Since Specialization

Citations

This map shows the geographic impact of Einar Haukås's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Einar Haukås with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Einar Haukås more than expected).

Fields of papers citing papers by Einar Haukås

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Einar Haukås. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Einar Haukås. The network helps show where Einar Haukås may publish in the future.

Co-authorship network of co-authors of Einar Haukås

This figure shows the co-authorship network connecting the top 25 collaborators of Einar Haukås. A scholar is included among the top collaborators of Einar Haukås based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Einar Haukås. Einar Haukås is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Title	Journal	Authors	Indexed citations
1	Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial	The Lancet Haematology	Einar Haukås, Tobias S. Slørdahl et al.	4
2	Replacing Steroids in Transplant-Ineligible Multiple Myeloma: The Phase 2 Isatuximab-Bortezomib-Lenalidomide-Dexamethasone Rest Study	Blood	Einar Haukås, Emil Hermansen et al.	1
3	P-349 Multiple Myeloma Patients Who Are in VGPR or Better Benefits From Continued Treatment With Zoledronic Acid Beyond Two Years	Clinical Lymphoma Myeloma & Leukemia	Thomas Lund, Annette Juul Vangsted et al.	2
4	OA-10 Four years treatment with zoledronic acid is superior to two years in protection against progressive bone disease in multiple myeloma	Clinical Lymphoma Myeloma & Leukemia	Fredrik Schjesvold, Annette Juul Vangsted et al.	1
5	Replacing Steroids in Transplant-Ineligible Multiple Myeloma: The Phase 2 Isatuximab-Bortezomib-Lenalidomide-Dexamethasone Rest Study	Blood	Einar Haukås, Tobias S. Slørdahl et al.	2
6	Will Survival Improve By Treating Multiple Myeloma Patients at MRD Relapse? the Remnant Study	Blood	Einar Haukås, Galina Tsykunova et al.	2
7	Paired miRNA- and messenger RNA-sequencing identifies novel miRNA-mRNA interactions in multiple myeloma	Scientific Reports	Einar Haukås, Tobias S. Slørdahl et al.	14
8	Comprehensive small RNA-sequencing of primary myeloma cells identifies miR-105-5p as a predictor of patient survival	British Journal of Cancer	Einar Haukås, Tobias S. Slørdahl et al.	5
9	P889: WILL OUTCOME IMPROVE BY TREATING MULTIPLE MYELOMA PATIENTS AT MRD RELAPSE? THE REMNANT STUDY (RELAPSE FROM MRD NEGATIVITY AS INDICATION FOR TREATMENT)	HemaSphere	Allan Rasmussen, Einar Haukås et al.	2
10	Replacing Steroids in Transplant-Ineligible Multiple Myeloma: The Phase 2 Isatuximab-Bortezomib-Lenalidomide-Dexamethasone Rest Study	Blood	Einar Haukås, Tobias S. Slørdahl et al.	1
11	A prospective study of Skeletal survey versus Low‐dose whole‐body CT for Osteolytic lesions in Multiple Myeloma	European Journal Of Haematology	Jon Thor Asmussen, Einar Haukås et al.	3
12	Ixazomib-Thalidomide-Low Dose Dexamethasone (ITd) Induction Followed By Maintenance Therapy with Ixazomib or Placebo in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem Cell Transplantation; Initial Results from the Randomized Phase II HOVON-126/Nmsg 21.13 Trial	University of Southern Denmark Research Portal (University of Southern Denmark)	Sonja Zweegman, Pieter Sonneveld et al.	0
13	Health-related quality of life in non-transplant eligible newly diagnosed multiple myeloma patients treated with melphalan/prednisolone plus either thalidomide or lenalidomide; results of the HOVON87/NMSG18 study	Pure Amsterdam UMC	Claudia A.M. Stege, Birgit I. Lissenberg‐Witte et al.	1
14	Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial	Blood	Sigbjørn Berentsen, Ulla Randen et al.	85
15	Overlevelse hos voksne med akutt lymfoblastisk leukemi	Tidsskrift for Den norske legeforening	Jon‐Magnus Tangen, Yngvar Fløisand et al.	2
16	Overlevelse hos voksne med akutt myelogen leukemi	Tidsskrift for Den Norske Laegeforening	Jon‐Magnus Tangen, Yngvar Fløisand et al.	1
17	[Survival in adults with acute myelogenous leukemia].	PubMed	Jon‐Magnus Tangen, Yngvar Fløisand et al.	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact